Jazz Pharmaceuticals stock
JAZZNASDAQJazz Pharmaceuticals plc, HealthcareISIN IE00B4Q5ZN47
66Score 66 out of 100, Neutral
Price and trend
81 / 100
Price history
+76% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.4% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 8.1% below its 52-week high. Largest decline in 19 years: 97% (June 2007 to April 2009).
Chart figures for advanced users
- SMA 50$229.25
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$219.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$136.71
- The lowest closing price of the last twelve months.
- Resistance$261.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Jazz Pharmaceuticals plc belongs to the Biotechnology industry (Ireland) and, with a market value of $15.43B, is number 23 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.27B (up 4.9% year on year) and a loss of $356.15M.
- For fiscal 2026, analysts expect on average revenue of $4.8B (up 12.5%) and adjusted earnings per share of $14.98 (up 82.7%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 198 of 702 in Healthcare, median 53.
- The P/E is 75.5 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 9.6 (Biotechnology median 21.7). The P/E therefore does not count in the score.
- Our model puts fair value at $590.09, with the price 59% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 76
- Below fair valuePrice 59% below the fair value of $590.09.Valuation 89
- Analysts expect strong earnings growthUp 31.8% a year through 2028 (estimates from 11 analysts).Growth 60
Weaknesses
- Margin fallingOperating margin 5.3%, average of the prior years 15.1% (to 2024).Profitability 52
- Turned to a lossEarnings per share from $4.28 in 2020 to −$5.84.Growth 60
- High debtDebt 1.35 times equity (latest quarter), Biotechnology median 0.09.Stability 47
Its standout strengths are valuation and momentum, while stability holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $453.91 and expensive above $842.98 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 11.8%. At 12.8% the fair value would be $512.44, at 10.8% it would be $690.81.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.5% on the twelve months before. Revenue has grown strongly since 2006, at around 27% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating 5%, net −8%. Last 12 months: net 4%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 2 Nov 2026EPS reported −$3.88 (expected −$4.03)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 39.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $14.98−39.3%
- Revenue
- $4.8B+1.7%
- Earnings per share
- $26.61+2.2%
- Revenue
- $5.05B+1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.5%2026 revenue guidance raised to $4.60 billion to $4.75 billion; Xywav is now expected to grow double digits instead of flat to up mid-single digits.
“We now expect total revenues in the range of $4.60 billion to $4.75 billion.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $47.98M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cozadd Bruce CSale
6 Nov 2026, Board
- Shares
- 68,808
- Price
- $235.95
- Value
- $16.24M
- Carr PatriciaSale
4 Nov 2026, SVP, Chief Accounting Officer
- Shares
- 1,413
- Price
- $231.36
- Value
- $326,910
- Gala Renee DSale
3 Nov 2026, President & CEO
- Shares
- 1,000
- Price
- $225.37
- Value
- $225,370
Show 15 more
- Cozadd Bruce CSale
2 Nov 2026, Board
- Shares
- 6,000
- Price
- $215.84
- Value
- $1.3M
- Gala Renee DSale
6 Oct 2026, President & CEO
- Shares
- 2,000
- Price
- $236.40
- Value
- $472,800
- Cozadd Bruce CSale
1 Oct 2026, Board
- Shares
- 6,000
- Price
- $230.33
- Value
- $1.38M
- Patil Neena MSale
10 Sept 2026, EVP & Chief Legal Officer
- Shares
- 1,200
- Price
- $240.94
- Value
- $289,128
- Gala Renee DSale
8 Sept 2026, President & CEO
- Shares
- 2,000
- Price
- $243.03
- Value
- $486,060
- Cozadd Bruce CSale
1 Sept 2026, Board
- Shares
- 6,000
- Price
- $250.13
- Value
- $1.5M
- Iannone RobertSale
27 Aug 2026, EVP, Global Head of R&D & CMO
- Shares
- 76,921
- Price
- $249.70
- Value
- $19.21M
- Cozadd Bruce CSale
3 Aug 2026, Board
- Shares
- 6,000
- Price
- $252.98
- Value
- $1.52M
- Cozadd Bruce CSale
1 Jul 2026, Board
- Shares
- 6,000
- Price
- $240.47
- Value
- $1.44M
- Smith Mark DouglasSale
15 Jun 2026, Board
- Shares
- 1,157
- Price
- $230.55
- Value
- $266,746
- Patil Neena MSale
10 Jun 2026, EVP & Chief Legal Officer
- Shares
- 1,200
- Price
- $231.83
- Value
- $278,196
- Patil Neena MSale
28 May 2026, EVP & Chief Legal Officer
- Shares
- 1,192
- Price
- $236.97
- Value
- $282,468
- Pearce SamanthaSale
28 May 2026, EVP, Chief Commercial Officer
- Shares
- 6,907
- Price
- $235.41
- Value
- $1.63M
- Winningham Rick ESale
22 May 2026, Board
- Shares
- 2,741
- Price
- $241.57
- Value
- $662,143
- McSharry Heather AnnSale
22 May 2026, Board
- Shares
- 2,000
- Price
- $241.00
- Value
- $482,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Jazz Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Innovent Biologics1801.HK $19.28B61
- Ascendis PharmaASND $17.57B69
- ExelixisEXEL $17.55B90
- Neurocrine BiosciencesNBIX $17.15B77
- BridgeBio PharmaBBIO $15.23B49
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.9B49
- Kymera TherapeuticsKYMR $12.73B45
- Madrigal PharmaceuticalsMDGL $12.44B33
ETFs that hold Jazz Pharmaceuticals
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.36% | 0.49% | €26.29M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.16% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.97% | 0.35% | €1.25B |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.50% | 0.40% | €813.42M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.44% | 0.30% | €5.36B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.26% | 0.43% | €2.5B |
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.26% | 0.75% | €142.73M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.16% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.